Delivery Order SPE2DB22D2214-SPE2DB25FS6EW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.54 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open contracting vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,049.47 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed price delivery order represents a non-set-aside competitive award for pharmaceutical products to support federal medical procurement needs. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $10,187.12 delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, competitively awarded delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The contractor, headquartered in Conshohocken, Pennsylvania, will perform the delivery at this same location. This award falls...
- The Defense Logistics Agency awarded a delivery order valued at $4,733.29 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count bottles) under a firm fixed-price contract. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary...
- The Defense Logistics Agency awarded a delivery order valued at $36,196.14 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was awarded without set-aside designation through competitive procedures and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,054.55 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCZ 160-25 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's substantial pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,539.63 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units. The contract employs firm fixed price pricing and carries an ultimate completion date of August 25, 2025, just three days after the award date of August 22, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCT 160-25 mg tablets (90-count) valued at $2,284.16, with an ultimate completion date of September 2, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $6,356.18 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,845.99 firm fixed price delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 11, 2025, with completion targeted for August 12, 2025. This non-set-aside competitive award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is the contractor's corporate...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6EWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,582.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This non-competitive delivery order utilizes firm fixed pricing and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime vendor contract functions as a comprehensive global pharmaceutical support vehicle, enabling the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The underlying IDC demonstrates the company's capacity to fulfill federal medical supply requirements across multiple therapeutic domains, with delivery orders consistently executed under firm fixed pricing arrangements ranging from minimal to substantial transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 8/19/25 |